PL2413956T3 - Identyfikacja, optymalizacja oraz zastosowanie kryptycznych epitopów antygenu hla-a24 na potrzeby immunoterapii - Google Patents
Identyfikacja, optymalizacja oraz zastosowanie kryptycznych epitopów antygenu hla-a24 na potrzeby immunoterapiiInfo
- Publication number
- PL2413956T3 PL2413956T3 PL09785926T PL09785926T PL2413956T3 PL 2413956 T3 PL2413956 T3 PL 2413956T3 PL 09785926 T PL09785926 T PL 09785926T PL 09785926 T PL09785926 T PL 09785926T PL 2413956 T3 PL2413956 T3 PL 2413956T3
- Authority
- PL
- Poland
- Prior art keywords
- immunotherapy
- epitopes
- optimization
- identification
- cryptic hla
- Prior art date
Links
- 108010013476 HLA-A24 Antigen Proteins 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000005457 optimization Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2009/005753 WO2010112962A1 (fr) | 2009-04-02 | 2009-04-02 | Identification, optimisation et utilisation d'épitopes hla-a24 cryptiques pour une immunothérapie |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2413956T3 true PL2413956T3 (pl) | 2017-06-30 |
Family
ID=41381983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL09785926T PL2413956T3 (pl) | 2009-04-02 | 2009-04-02 | Identyfikacja, optymalizacja oraz zastosowanie kryptycznych epitopów antygenu hla-a24 na potrzeby immunoterapii |
Country Status (13)
Country | Link |
---|---|
US (1) | US8900600B2 (fr) |
EP (1) | EP2413956B1 (fr) |
JP (1) | JP5756792B2 (fr) |
CN (1) | CN102387813B (fr) |
BR (1) | BRPI0924827A2 (fr) |
CA (1) | CA2756238A1 (fr) |
DK (1) | DK2413956T3 (fr) |
ES (1) | ES2608715T3 (fr) |
HR (1) | HRP20161710T1 (fr) |
HU (1) | HUE030195T2 (fr) |
PL (1) | PL2413956T3 (fr) |
PT (1) | PT2413956T (fr) |
WO (1) | WO2010112962A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102341899B1 (ko) * | 2013-04-07 | 2021-12-21 | 더 브로드 인스티튜트, 인코퍼레이티드 | 개인맞춤화 신생물 백신을 위한 조성물 및 방법 |
JP6788500B2 (ja) | 2013-10-23 | 2020-11-25 | アメリカ合衆国 | Muc1−c癌タンパク質のhla−a24アゴニストエピトープ及び組成物及び使用方法 |
WO2015077717A1 (fr) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn |
WO2015085147A1 (fr) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Typage de gènes polymorphes et détection de changements somatiques à l'aide de données de séquençage |
EP2886127A1 (fr) * | 2013-12-18 | 2015-06-24 | Vaxon Biotech | Procédé d'émulsification d'un peptide triepitope avec montanide et kits permettant de mettre en oeuvre celui-ci |
JP7060324B2 (ja) | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
EP2977059A1 (fr) * | 2014-07-22 | 2016-01-27 | Vaxon Biotech | Polypeptide immunogène composé de peptides cryptiques optimisés dérivés d'antigènes tumoraux restreints hla-b7 et leurs utilisations |
WO2016100975A1 (fr) | 2014-12-19 | 2016-06-23 | Massachsetts Institute Ot Technology | Biomarqueurs moléculaires pour l'immunothérapie d'un cancer |
EP3234130B1 (fr) | 2014-12-19 | 2020-11-25 | The Broad Institute, Inc. | Procédé pour profiler le répertoire de récepteurs de cellulles t. |
CR20200476A (es) | 2015-05-20 | 2020-12-02 | Dana Farber Cancer Inst Inc | ANTÍGENOS COMPARTIDOS (Divisional 2017-0584) |
EP3574116A1 (fr) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions et procédés de détection d'un variant mutant d'un polynucléotide |
MX2021010537A (es) * | 2019-03-04 | 2021-12-10 | Univ Health Network | Receptores de linfocitos t y metodos de uso de estos. |
CN111363026B (zh) * | 2020-03-31 | 2022-03-25 | 浙江省中医院、浙江中医药大学附属第一医院(浙江省东方医院) | 一种增强抗原多肽亲和力和稳定性的方法 |
WO2024138753A1 (fr) * | 2022-12-30 | 2024-07-04 | 深圳吉诺因生物科技有限公司 | Procédé de remplacement de site antigénique restrictif hla-a*24:02, polypeptide obtenu et son utilisation |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6337200B1 (en) | 1998-03-31 | 2002-01-08 | Geron Corporation | Human telomerase catalytic subunit variants |
EP1455816A4 (fr) * | 2000-10-19 | 2007-03-28 | Epimmune Inc | Peptides de liaison hla de classe i et ii et leurs utilisations |
JP4624377B2 (ja) * | 2001-12-10 | 2011-02-02 | 株式会社グリーンペプタイド | 腫瘍抗原 |
EP1462456A4 (fr) * | 2001-12-10 | 2005-09-21 | Greenpeptide Co Ltd | Antigenes tumoraux |
WO2003087126A2 (fr) * | 2002-04-05 | 2003-10-23 | Epimmune Inc. | Analogues heteroclitiques et procedes associes |
CN101434647A (zh) | 2004-01-20 | 2009-05-20 | 爱知县 | 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用 |
WO2007094924A2 (fr) | 2006-01-19 | 2007-08-23 | The Regents Of The University Of California | Peptides de la transcriptase inverse de la télomérase humaine |
WO2008010010A1 (fr) | 2006-07-12 | 2008-01-24 | Vaxon Biotech | Identification, optimisation et utilisation d'épitopes cryptiques hla-b7 en immunothérapie |
-
2009
- 2009-04-02 CN CN200980158591.2A patent/CN102387813B/zh active Active
- 2009-04-02 BR BRPI0924827A patent/BRPI0924827A2/pt not_active Application Discontinuation
- 2009-04-02 WO PCT/IB2009/005753 patent/WO2010112962A1/fr active Application Filing
- 2009-04-02 HU HUE09785926A patent/HUE030195T2/en unknown
- 2009-04-02 PT PT97859268T patent/PT2413956T/pt unknown
- 2009-04-02 PL PL09785926T patent/PL2413956T3/pl unknown
- 2009-04-02 JP JP2012502822A patent/JP5756792B2/ja active Active
- 2009-04-02 ES ES09785926.8T patent/ES2608715T3/es active Active
- 2009-04-02 CA CA2756238A patent/CA2756238A1/fr not_active Abandoned
- 2009-04-02 US US13/258,227 patent/US8900600B2/en active Active
- 2009-04-02 DK DK09785926.8T patent/DK2413956T3/en active
- 2009-04-02 EP EP09785926.8A patent/EP2413956B1/fr active Active
-
2016
- 2016-12-13 HR HRP20161710TT patent/HRP20161710T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
US20120082692A1 (en) | 2012-04-05 |
HUE030195T2 (en) | 2017-04-28 |
ES2608715T3 (es) | 2017-04-12 |
CN102387813A (zh) | 2012-03-21 |
JP2012522500A (ja) | 2012-09-27 |
US8900600B2 (en) | 2014-12-02 |
DK2413956T3 (en) | 2017-01-09 |
HRP20161710T1 (hr) | 2017-02-24 |
CN102387813B (zh) | 2018-07-31 |
JP5756792B2 (ja) | 2015-07-29 |
BRPI0924827A2 (pt) | 2019-01-08 |
WO2010112962A1 (fr) | 2010-10-07 |
PT2413956T (pt) | 2016-12-30 |
EP2413956A1 (fr) | 2012-02-08 |
EP2413956B1 (fr) | 2016-09-14 |
CA2756238A1 (fr) | 2010-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2413956T (pt) | Identificação, optimização e utilização de epitopos crípticos hla-a24 para imunoterapia | |
EP2429585A4 (fr) | Immunothérapie par vaccin | |
IL240898A0 (en) | Antibodies against a5c and methods of using the antibodies | |
EP2593098A4 (fr) | Procédés et compositions pour l'immunothérapie du cancer | |
EP2644151A4 (fr) | Implant, corps d'implant, et corps de butée | |
IL221417A0 (en) | Abrasive articles, method for their preparation and method of their use | |
EP2762488A4 (fr) | Peptide pour la synthèse de la silice, et son utilisation | |
GB0905570D0 (en) | Combined vaccines | |
EP2612911A4 (fr) | Composition pour induire une cellule souche pluripotente, et utilisation de cette composition | |
EP2561072A4 (fr) | Nanozymes, procédés de production de nanozymes, et procédés d'utilisation de nanozymes | |
EP2550269A4 (fr) | Procédé et intermédiaires pour la préparation du lapatinib | |
PL2444103T3 (pl) | Szczepionka przeciwko rakowi szyjki macicy | |
HK1169424A1 (en) | Identification, optimization and use of shared hla-b0702 epitopes for immunotherapy hla-b0702 | |
PT2391589E (pt) | Clínquer sulfo-aluminoso e processo para a sua preparação | |
EP2408473A4 (fr) | Procédés de vaccination | |
EP2573072A4 (fr) | Composé d'indénoquinolone, son procédé de préparation et son utilisation | |
EP2486890A4 (fr) | Butée pour implant | |
EP2575888A4 (fr) | Immunisation par voie nasale | |
EP2881385A4 (fr) | Nouveau composé azo, son utilisation et son procédé de préparation | |
HK1202070A1 (en) | Vaccine for tumor immunotherapy | |
IL216102A0 (en) | Combined measles-malaria vaccine | |
ZA201302213B (en) | Centering aid for implantable sling | |
EP2701504A4 (fr) | Dérivés du sulindac, leur utilisation et leur préparation | |
AP2013006816A0 (en) | Ptocess for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation | |
AP3680A (en) | Glans retainer |